We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bruker's Buyout of Canopy Biosciences Enhances Portfolio
Read MoreHide Full Article
Bruker Corporation (BRKR - Free Report) recently announced the acquisition of Canopy Biosciences, LLC. The buyout of the renowned high multiplex biomarker imaging enhances Bruker’s portfolio of targeted multi-omics and fluorescence-based imaging techniques.
However, the financial details of the deal have been kept under wraps.
With the latest buyout, Bruker aims to strengthen its position in immunology, immuno-oncology and cell therapy. Canopy Biosciences business will be integrated within Bruker Scientific Instruments ("BSI") Nano segment.
Rationale Behind the Deal
Per management, the buyout of Canopy Biosciences incorporates the latter’s multi-omics and high-content cytometry expertise as well as its ChipCytometry platform. This will enable Bruker to enhance its own portfolio.
Bruker’s global presence, complementary technologies and applications knowledge will be beneficial for both the companies. Meanwhile, Canopy Biosciences’ products enable cell and tissue-based discovery and validation in immunology and targeted proteomics. It also offers a suite of complementary multi-omics services, which will add to Bruker’s existing imaging techniques.
The buyout will enable a greater number of researchers to gain access to the high-plex ChipCytometry platform, which has been designed for accelerating basic immunology and clinical research along with biopharma drug development.
Industry Prospects
Per a report by Polaris Market Research, the global immuno-oncology market was estimated at $12 billion in 2019 and is expected to see a CAGR of 21.8% between 2020 and 2025. Per a Grand View Research report, the global cell therapy market size was valued at $5.8 billion in 2019 and is expected to reach $8.8 billion by 2027, at a CAGR of 5.4%.
Factors like rising incidence of cancer and technological advancements made with respect to treating the same are likely to drive the market.
Given the market prospects, the acquisition seems to have been timed well.
Recent Developments
Of late, Bruker has witnessed some important business developments.
The company, in August, entered into a collaboration with Utrecht University to advance the study of the 3-D structures and interactions of proteins by mass spectrometry.
In July, Bruker launched the high-speed NanoRacerhigh-speed atomic force microscopy (“AFM”) system, which sets a new milestone in high-speed scanning capabilities to enable true real-time visualization of dynamic biological processes using AFM.
In the same month, the company launched its FluoroType SARS-CoV-2 plus next-generation 6-plex polymerase chain reaction assay for higher specific detection of the SARS-CoV-2, the COVID-19-causing virus.
Further, in July, Bruker announced the successful installation and customer acceptance of the Avance NEO 1.2 GHz NMR system at the Department of Chemistry and Applied Biosciences of the Eidgenössische Technische Hochschule Zürich in Switzerland.
The company, in May, launched the world’s first commercial MALDI-2 post-ionization source, which is currently available as an option on the timsTOF fleX ESI/MALDI mass spectrometer.
Price Performance
Shares of the company have lost 8.5% in the past year against the industry’s 10.9% rise and the S&P 500’s 13.7% rally.
Zacks Rank & Key Picks
Currently, Bruker carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are QIAGEN N.V. (QGEN - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) and Hologic, Inc. (HOLX - Free Report) .
Thermo Fisher’s long-term earnings-growth rate is estimated at 15.5%. It currently sports a Zacks Rank #1.
Hologic’s long-term earnings-growth rate is estimated at 15.5%. The company presently flaunts a Zacks Rank #1.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Image: Bigstock
Bruker's Buyout of Canopy Biosciences Enhances Portfolio
Bruker Corporation (BRKR - Free Report) recently announced the acquisition of Canopy Biosciences, LLC. The buyout of the renowned high multiplex biomarker imaging enhances Bruker’s portfolio of targeted multi-omics and fluorescence-based imaging techniques.
However, the financial details of the deal have been kept under wraps.
With the latest buyout, Bruker aims to strengthen its position in immunology, immuno-oncology and cell therapy. Canopy Biosciences business will be integrated within Bruker Scientific Instruments ("BSI") Nano segment.
Rationale Behind the Deal
Per management, the buyout of Canopy Biosciences incorporates the latter’s multi-omics and high-content cytometry expertise as well as its ChipCytometry platform. This will enable Bruker to enhance its own portfolio.
Bruker’s global presence, complementary technologies and applications knowledge will be beneficial for both the companies. Meanwhile, Canopy Biosciences’ products enable cell and tissue-based discovery and validation in immunology and targeted proteomics. It also offers a suite of complementary multi-omics services, which will add to Bruker’s existing imaging techniques.
The buyout will enable a greater number of researchers to gain access to the high-plex ChipCytometry platform, which has been designed for accelerating basic immunology and clinical research along with biopharma drug development.
Industry Prospects
Per a report by Polaris Market Research, the global immuno-oncology market was estimated at $12 billion in 2019 and is expected to see a CAGR of 21.8% between 2020 and 2025. Per a Grand View Research report, the global cell therapy market size was valued at $5.8 billion in 2019 and is expected to reach $8.8 billion by 2027, at a CAGR of 5.4%.
Factors like rising incidence of cancer and technological advancements made with respect to treating the same are likely to drive the market.
Given the market prospects, the acquisition seems to have been timed well.
Recent Developments
Of late, Bruker has witnessed some important business developments.
The company, in August, entered into a collaboration with Utrecht University to advance the study of the 3-D structures and interactions of proteins by mass spectrometry.
In July, Bruker launched the high-speed NanoRacerhigh-speed atomic force microscopy (“AFM”) system, which sets a new milestone in high-speed scanning capabilities to enable true real-time visualization of dynamic biological processes using AFM.
In the same month, the company launched its FluoroType SARS-CoV-2 plus next-generation 6-plex polymerase chain reaction assay for higher specific detection of the SARS-CoV-2, the COVID-19-causing virus.
Further, in July, Bruker announced the successful installation and customer acceptance of the Avance NEO 1.2 GHz NMR system at the Department of Chemistry and Applied Biosciences of the Eidgenössische Technische Hochschule Zürich in Switzerland.
The company, in May, launched the world’s first commercial MALDI-2 post-ionization source, which is currently available as an option on the timsTOF fleX ESI/MALDI mass spectrometer.
Price Performance
Shares of the company have lost 8.5% in the past year against the industry’s 10.9% rise and the S&P 500’s 13.7% rally.
Zacks Rank & Key Picks
Currently, Bruker carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are QIAGEN N.V. (QGEN - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) and Hologic, Inc. (HOLX - Free Report) .
QIAGEN’s long-term earnings-growth rate is estimated at 22.3%. It currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Thermo Fisher’s long-term earnings-growth rate is estimated at 15.5%. It currently sports a Zacks Rank #1.
Hologic’s long-term earnings-growth rate is estimated at 15.5%. The company presently flaunts a Zacks Rank #1.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Click here for the 6 trades >>